Revenue Breakdown
Composition ()
No data
Revenue Streams
Longeveron Inc (LGVN) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Clinical trial revenue, accounting for 68.6% of total sales, equivalent to $94.00K. Other significant revenue streams include Contract manufacturing and Contract manufacturing lease revenue. Understanding this composition is critical for investors evaluating how LGVN navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Evaluating the bottom line, Longeveron Inc maintains a gross margin of 91.24%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -5335.77%, while the net margin is -5270.80%. These profitability ratios, combined with a Return on Equity (ROE) of -119.92%, provide a clear picture of how effectively LGVN converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, LGVN competes directly with industry leaders such as IMNN and CRIS. With a market capitalization of $11.97M, it holds a leading position in the sector. When comparing efficiency, LGVN's gross margin of 91.24% stands against IMNN's N/A and CRIS's 71.66%. Such benchmarking helps identify whether Longeveron Inc is trading at a premium or discount relative to its financial performance.
